These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27775814)

  • 1. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing and analyzing clinical trials for personalized medicine via Bayesian models.
    Zhang C; Mayo MS; Wick JA; Gajewski BJ
    Pharm Stat; 2021 May; 20(3):573-596. PubMed ID: 33463906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian adaptive phase II clinical trial design accounting for spatial variation.
    Guo B; Zang Y
    Stat Methods Med Res; 2019; 28(10-11):3187-3204. PubMed ID: 30229695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian cancer clinical trial designs with subgroup-specific decisions.
    Thall PF
    Contemp Clin Trials; 2020 Mar; 90():105860. PubMed ID: 31678411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling.
    Zang Y; Guo B; Han Y; Cao S; Zhang C
    Stat Med; 2019 Jul; 38(15):2883-2896. PubMed ID: 30968435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials.
    Xiong W; Roy J; Liu H; Hu L
    Contemp Clin Trials; 2024 Jul; 142():107547. PubMed ID: 38688389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers.
    Yada S
    Int J Biostat; 2021 Jun; 18(1):109-125. PubMed ID: 34114385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.
    Zhang J; Lin R; Chen X; Yan F
    Clin Trials; 2024 Jun; 21(3):308-321. PubMed ID: 38243401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
    Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
    J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
    Lin JA; He P
    Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.
    Guo B; Zang Y
    Stat Methods Med Res; 2022 Jun; 31(6):1104-1119. PubMed ID: 35191780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.